CN Patent

CN113727719A — 血癌的新型治疗方法及新型治疗剂

Assigned to Delta Fly Pharma Inc · Expires 2021-11-30 · 4y expired

What this patent protects

本发明的目的在于提供用于对血癌患者进行治疗或缓解的、能实现高效果并且副作用少的新手段，本发明涉及组合药物，其在用于血癌患者的治疗或缓解的方法中使用，所述组合药物包含4‑氨基‑1‑(2‑氰基‑2‑脱氧‑β‑D‑阿拉伯呋喃糖基)‑2(1H)‑嘧啶酮或其盐和维奈托克或其盐。

USPTO Abstract

本发明的目的在于提供用于对血癌患者进行治疗或缓解的、能实现高效果并且副作用少的新手段，本发明涉及组合药物，其在用于血癌患者的治疗或缓解的方法中使用，所述组合药物包含4‑氨基‑1‑(2‑氰基‑2‑脱氧‑β‑D‑阿拉伯呋喃糖基)‑2(1H)‑嘧啶酮或其盐和维奈托克或其盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN113727719A
Jurisdiction
CN
Classification
—
Expires
2021-11-30
Drug substance claim
No
Drug product claim
No
Assignee
Delta Fly Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.